PETALING JAYA: Earnings contribution for the potential supply of Sinopharm Covid-19 vaccine to the government by Duopharma Biotech Bhd
is expected to be marginal.
The company on Friday received a conditional registration approval for the vaccine and is likely to sign an agreement by month-end with more details to be announced then.
Duopharma is also awaiting approval to supply Russia’s Sputnik V vaccine (pic below) to the Malaysian government. But for now, even the World Health Organisation has yet to approve the Sputnik vaccine for Covid-19.
Sputnik vaccine
...